

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

Chlorhexidine Gluconate for Skin Preparation During Stereotactic Core Biopsy of the Breast: Clinical Effectiveness and Guidelines

Service Line: Rapid Response Service
Version: 1.0
Publication Date: February 08, 2019
Report Length: 6 Pages

Authors: Deba Hafizi, Suzanne McCormack

Cite As: Chlorhexidine Gluconate for Skin Preparation During Stereotactic Core Biopsy of the Breast: Clinical Effectiveness and Guidelines. Ottawa: CADTH; 2019 Feb. (CADTH rapid response report: summary of abstracts).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Research Questions

1. What is the clinical effectiveness of chlorhexidine gluconate wipes for female adults undergoing skin preparation during stereotactic core biopsy of the breast?
2. What are the evidence-based guidelines associated with skin preparation during stereotactic core biopsy of the breast?

Key Findings

No relevant clinical evidence or evidence-based guidelines were identified regarding chlorhexidine gluconate wipes for female adults undergoing skin preparation during stereotactic core biopsy of the breast.

Methods

A limited literature search was conducted on key resources including PubMed, the Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. For Q1, no filters were applied to limit the retrieval by study type. For Q2, methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses and guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2009, and February 4, 2019. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

| | |
|----------------------|--|
| Population | Female adults undergoing skin preparation during stereotactic core biopsy of the breast |
| Intervention | Chlorhexidine gluconate swabs/wipes |
| Comparator | Q1: Alcohol; Other swab preparations; No comparator Q2: No comparator |
| Outcomes | Q1: Clinical effectiveness (e.g., prevention of biopsy site infections, ease or speed of drying, comparative effectiveness versus alcohol) and safety (e.g., clinical benefit or harm [e.g., skin irritation]) Q2: Guidelines |
| Study Designs | Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, evidence-based guidelines |

Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, or evidence-based guidelines were identified regarding chlorhexidine gluconate wipes for female adults undergoing skin preparation during stereotactic core biopsy of the breast.

References of potential interest are provided in the appendix.

Overall Summary of Findings

No relevant literature was identified regarding chlorhexidine gluconate for skin preparation during stereotactic core biopsy of the breast; therefore, no summary can be provided.

References Summarized

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

No literature identified.

Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

No literature identified.

Guidelines and Recommendations

No literature identified.

Appendix — Further Information

Previous CADTH Reports – Not Specific to Breast Biopsy

1. Chlorhexidine gluconate wipes for infection prevention in acute and critical care: a review of clinical effectiveness and cost-effectiveness. (CADTH Rapid response report: summary with critical appraisal). Ottawa (ON): CADTH; 2016.
<https://www.cadth.ca/sites/default/files/pdf/htis/apr-2016/RC0769%20Chlorhexidine%20Wipes%20Final.pdf>. Accessed 2019 Feb 7.
2. Chlorhexidine impregnated wipes for pre-operative skin preparation: clinical evidence and guidelines. (CADTH Rapid response report: summary of abstracts). Ottawa (ON): CADTH; 2012.
<https://cadth.ca/sites/default/files/pdf/htis/dec-2012/RB0551%20PreOp%20Skin%20Wipes%20Final.pdf>. Accessed 2019 Feb 7.

Health Technology Assessments – Alternative Comparator

3. Use of 4% chlorhexidine gluconate products for reducing hospital-acquired infections. Plymouth Meeting (PA): ECRI Institute; 2017.
4. Preoperative skin preparation with chlorhexidine gluconate products for reducing surgical site infections. Plymouth Meeting (PA): ECRI Institute; 2017.

Randomized-Controlled Trials – Recruitment Status Unknown

Specific to Surgery

5. Wound infections in breast cancer surgery after preoperative skin preparation with chlorhexidine vs. povidone-iodine. Milan (IT): Fondazione IRCCS Istituto Nazionale dei Tumori; 2015. <https://clinicaltrials.gov/ct2/show/NCT02479347>. Accessed 2019 Feb 7.

Non-Randomized Studies – Alternative Population

6. Heckmann N, Sivasundaram L, Heidari KS, et al. Propionibacterium Acnes Persists Despite Various Skin preparation Techniques. *Arthroscopy*. 2018 Jun;34(6):1786-1789. [PubMed: PM29580742](https://pubmed.ncbi.nlm.nih.gov/30295807/)

Guidelines and Recommendations

Alternative Population: Pre-Surgical

7. Global guidelines for the prevention of surgical site infection. Geneva (CH): World Health Organization (WHO); 2016.
<https://apps.who.int/iris/bitstream/handle/10665/250680/9789241549882-eng.pdf>. Accessed 2019 Feb 7.
See: 4.7 Surgical site preparation, page 87

Alternative Comparator

8. Routine Practices and Additional Precautions for Preventing the Transmission of Infection in Healthcare Settings. Ottawa (ON): Public Health Agency of Canada; 2013. <https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/routine-practices-precautions-healthcare-associated-infections/routine-practices-precautions-healthcare-associated-infections-2016-FINAL-eng.pdf>. Accessed 2019 Feb 7.
See: "Routine practices—Aseptic technique for injections and intravascular and other invasive procedures," page 49 for general antiseptic guidelines

Review Articles

9. Newell MS, Mahoney MC. Ultrasound-guided percutaneous breast biopsy. *Tech Vasc Interv Radiol*. 2014 Mar;17(1):23-31. doi: 10.1053/j.tvir.2013.12.005. [https://www.techvir.com/article/S1089-2516\(13\)00091-7/pdf](https://www.techvir.com/article/S1089-2516(13)00091-7/pdf). Accessed 2019 Feb 7.
See: Page 26, first paragraph